0.1129  -0.013 (-10.11%)		01-08 09:36
Open: 0.1645 High: 0.1645 Volume: 13,085,674		Pre. Close: 0.1256 Low: 0.1108 Market Cap: 6(M)

Short term
Mid term
Targets	6-month :	0.19	1-year :	0.23
Resists	First :	0.17	Second :	0.19
Pivot price	0.11
Supports	First :	0.1	Second :	0.07
MAs	MA(5) :	0.12	MA(20) :	0.1
	MA(100) :	0.28	MA(250) :	1.66
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	37.7	D(3) :	51.8
RSI	RSI(14): 51.2
52-week	High :	15.8	Low :	0.07

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ASBP ] has closed below upper band by 26.5%. Bollinger Bands are 68% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 25 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.17 - 0.17	0.17 - 0.17
Low:	0.12 - 0.12	0.12 - 0.12
Close:	0.12 - 0.13	0.13 - 0.13

Aspire Biopharma Holdings, Inc. is a biotechnology company specializing in advanced diagnostic solutions and molecular testing. The company focuses on developing high-precision assays for disease detection, leveraging cutting-edge research in genetics and biochemistry to support healthcare and life sciences industries.

Thu, 08 Jan 2026
FDA feedback clears path for Aspire Biopharma’s heart attack drug By Investing.com - Investing.com Nigeria

Wed, 07 Jan 2026
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga

Wed, 07 Jan 2026
Aspire Biopharma stock soars after FDA meeting clears path for heart attack drug By Investing.com - Investing.com South Africa

Wed, 07 Jan 2026
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA) - Weatherford Democrat

Wed, 07 Jan 2026
FDA backs trial of faster-acting aspirin powder for heart attacks - Stock Titan

Wed, 07 Jan 2026
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA) - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	138 (M)
Held by Insiders	9.167e+007 (%)
Held by Institutions	13.9 (%)
Shares Short	4,700 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-59 %
Return on Assets (ttm)	15.8 %
Return on Equity (ttm)	-195.2 %
Qtrly Rev. Growth	1940 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	1016.09
Qtrly Earnings Growth	-0.7 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-4 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	-0.48

Dividend	0
Forward Dividend	1.353e+007
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.